Form 8-K

8-K — Endovia Health Sciences, Inc.

Accession: 0001731122-26-001312

Filed: 2026-10-05

Period: 2026-10-05

CIK: 0001553788

SIC: 2080 (BEVERAGES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7991_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7991_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7991_8k.htm · Sequence: 1

false

0001553788

2026-10-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 5, 2026

ENDOVIA

HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40471

34-1720075

(State or other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1112 N. Flagler Drive

Fort Lauderdale, Florida

33304

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code: (954) 648-7238

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange

Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of

the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SBEV

NYSE American LLC

Item 7.01 Regulation FD Disclosure

On October 5, 2026, Endovia Health Sciences, Inc.

(the “Company”) issued a press release announcing the U.S. Food and Drug Administration’s determination that CannEpil®

qualifies as a minor use for canine bone cancer pain. A copy of the press release is furnished as Exhibit 99.1 of this Current Report

on Form 8-K.

The information in this Item 7.01 (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)

or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of

the Company under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

Description

99.1

Press Release dated October 5, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

SIGNATURES

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

ENDOVIA HEALTH SCIENCES, INC.

Date: October 5, 2026

By:

/s/ Brady Cobb

Name:

Brady Cobb

Title:

Interim Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7991_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Endovia and Lupvindol BioSciences Announce FDA Determination

that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

Companies to Meet Formally with FDA’s Center

for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027

Veterinary Product Launch

FORT LAUDERDALE, Fla. — October 5, 2026 — Endovia Health Sciences,

Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”),

today announced that the U.S. Food and Drug Administration’s (“FDA”) Center for Veterinary Medicine has determined that

the proposed use of CannEpil®, an investigational cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oral

solution, for the control of pain associated with bone cancer in dogs qualifies as a “minor use” under the Minor Use and Minor

Species (“MUMS”) program.

The FDA determination establishes CannEpil’s eligibility to pursue

the conditional approval pathway for this proposed indication. The FDA further determined that the minor-use status will be maintained

through approval of the applicable New Animal Drug Application (“NADA”).

Under the MUMS framework, qualifying new animal drugs may be eligible for

conditional approval which is a regulatory pathway designed to facilitate earlier availability of therapies for uncommon diseases and

conditions in animals. Conditional approval requires satisfaction of applicable FDA requirements, including safety and manufacturing standards

and a reasonable expectation of effectiveness, while allowing additional effectiveness data required for full approval to be collected

following conditional approval.

Endovia and Lupvindol are scheduled to meet formally with the FDA on November

19, 2026, for a Pre-Submission Conference to discuss and align with the FDA on the proposed CannEpil® development program,

including the studies, manufacturing requirements and regulatory submissions necessary to pursue conditional approval.

In parallel with the regulatory program, Endovia and Lupvindol are actively

sourcing and finalizing U.S.-based manufacturing capabilities for CannEpil®. This work is intended to establish a scalable,

FDA-compliant domestic supply chain capable of supporting the clinical and regulatory program and, subject to receipt of the necessary

regulatory approvals, a potential commercial launch for veterinary use in 2027.

“This determination represents an important regulatory milestone

for CannEpil® and provides greater clarity around the pathway we are pursuing with the FDA,” said Brady Cobb, Interim

Chief Executive Officer of Endovia Health Sciences. “Importantly, we are not waiting to begin preparing for commercialization. Alongside

Lupvindol, we are advancing our FDA development program while simultaneously working to establish U.S. manufacturing and supply capabilities

that can support a potential veterinary launch in 2027, subject to regulatory approval.”

Cobb continued, “We believe CannEpil has the potential to demonstrate

what a science-driven, federally regulated cannabinoid medicine can look like in the United States. Our veterinary program gives us an

opportunity to address a serious unmet need for dogs suffering from cancer-related pain while building the regulatory, manufacturing and

scientific infrastructure that we believe can support the broader development of CannEpil.”

The MUMS conditional approval pathway was established to encourage development

of new animal drugs for uncommon conditions affecting relatively small populations. Following conditional approval, a sponsor may legally

market a qualifying animal drug while continuing to collect the additional effectiveness data necessary to support full FDA approval,

subject to applicable statutory and regulatory requirements and annual FDA renewal.

CannEpil® remains an investigational new animal drug and

has not been approved or conditionally approved by the FDA. The Company’s anticipated development timelines, including a potential

2027 commercial launch, remain subject to FDA review, successful completion of applicable regulatory requirements, manufacturing readiness

and other factors.

About CannEpil®

CannEpil® is a proprietary cannabinoid-based oral formulation containing

cannabidiol (CBD) and tetrahydrocannabinol (THC). Endovia and Lupvindol BioSciences are advancing CannEpil through the FDA’s Center

for Veterinary Medicine for the proposed control of pain associated with bone cancer in dogs.

The veterinary development program is part of Endovia’s broader strategy

to develop cannabinoid-based therapeutics through established federal regulatory pathways and to build a platform capable of supporting

additional veterinary and human therapeutic applications, subject to applicable statutory and regulatory requirements.

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health

sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics,

international pharmaceutical commercialization and cannabinoid-based wellness products.

About Lupvindol Biosciences Ltd.

Lupvindol Biosciences Ltd. is a pharmaceutical and bioscience development

company with expertise in cannabinoid-based therapeutics and U.S. FDA regulatory pathways. The company is led by Hunter Land, Ph.D., whose

experience includes participation in the development of Epidiolex® and Sativex® at GW Pharmaceuticals.

Forward-Looking Statements

This press release contains “forward-looking statements” within

the meaning of the Private Securities Litigation Reform act of 1995 including statements regarding the development and commercialization

of CannEpil®; obtaining a manufacturing source, and a potential commercial veterinary launch in 2027.

Forward-looking statements are based on current expectations, estimates,

projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Some or all of these

risks may not occur. These risks include the Company’s ability to obtain additional financing; the development of and obtaining

regulatory authorization for and commercialize CannEpil® for veterinary use, the results of any clinical trials, the availability

of raw materials, the ability to obtain a manufacturer to meet our needs on a financially viable basis, ; maintaining its rights under

applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; ability to meet

competition from both CBD and conventional pharmaceuticals products ,our ability to successfully execute commercialization or strategic-partnering

arrangements, and the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less

than expected or projected.

Additional risks are described in the Company’s filings with the

Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and

the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release,

and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events

or otherwise, except as required by applicable law.

Investor Contact

Endovia Health Sciences

investors@endoviasciences.com

Media Contact

Angela Gorman

AMWPR

angela@amwpr.com

917-348-0083

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 05, 2026

Entity File Number

001-40471

Entity Registrant Name

ENDOVIA

HEALTH SCIENCES, INC.

Entity Central Index Key

0001553788

Entity Tax Identification Number

34-1720075

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1112 N. Flagler Drive

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33304

City Area Code

(954)

Local Phone Number

648-7238

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

SBEV

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration